Individuals with diabetes and hypertension are especially at risk and should undergo screening for NAFLD (Non-Alcoholic Fatty ...

Researchers at MD Anderson discussed the five possible approaches to treating graft-versus-host disease in a review article ...

In this edition of Open Interest, we look at how the focus on GLP-1 could reduce household dietary intake and grocery bills.

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...

The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...

Semaglutide Treats Liver Disease in Two Thirds of Patients Apr. 30, 2025 — Semaglutide effectively treats liver disease in two thirds of patients, new research has ... Apr. 15, 2025 ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing ...

During the first meeting of the Global Think-tank on Steatotic Liver Disease, supported by the Barcelona Institute for Global ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes. Here are four t ...

Diabetic weight loss medications are effective for people with schizophrenia without affecting psychotic symptoms, University ...

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...